JP7855519B2 - がんを処置するための抗ｃｃｒ８抗体 - Google Patents

がんを処置するための抗ｃｃｒ８抗体

Info

Publication number
JP7855519B2
JP7855519B2 JP2022557776A JP2022557776A JP7855519B2 JP 7855519 B2 JP7855519 B2 JP 7855519B2 JP 2022557776 A JP2022557776 A JP 2022557776A JP 2022557776 A JP2022557776 A JP 2022557776A JP 7855519 B2 JP7855519 B2 JP 7855519B2
Authority
JP
Japan
Prior art keywords
sequence
seq
amino acids
linked amino
sequence described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022557776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519254A (ja
JP2023519254A5 (enExample
Inventor
イン－ゾン ラン，ルース
エイ アデラクン，オルフェミ
バルマン，イシタ
リチャード キャンベル，ジョセフ
ジエン ジョー ディオン，エスジェイ
フィンダイゼン，フェリックス
エム グリーナウォルト，ダニエル
ジャイン，レニュ
ディ ジャタキア，エイミー
ケイ リー，ジョン
ソンギュン リー，ピーター
リアン，リンダ
ルー，カイ
マクドナルド，ブライアン
ブレイン メスコ，ポール
ラジパル，アルビンド
サンバンタムールティ，シャルミラ
ジェイ セルビー，マーク
オー シーマーズ，ネイサン
ストロップ，パベル
エイ テッラチーナ，ゲイビー
ワン，シー－タオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023519254A publication Critical patent/JP2023519254A/ja
Publication of JP2023519254A5 publication Critical patent/JP2023519254A5/ja
Application granted granted Critical
Publication of JP7855519B2 publication Critical patent/JP7855519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2022557776A 2020-03-23 2021-03-22 がんを処置するための抗ｃｃｒ８抗体 Active JP7855519B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062993570P 2020-03-23 2020-03-23
US62/993,570 2020-03-23
US202063041992P 2020-06-21 2020-06-21
US63/041,992 2020-06-21
US202163157618P 2021-03-05 2021-03-05
US63/157,618 2021-03-05
PCT/US2021/023430 WO2021194942A1 (en) 2020-03-23 2021-03-22 Anti-ccr8 antibodies for treating cancer

Publications (3)

Publication Number Publication Date
JP2023519254A JP2023519254A (ja) 2023-05-10
JP2023519254A5 JP2023519254A5 (enExample) 2024-06-26
JP7855519B2 true JP7855519B2 (ja) 2026-05-08

Family

ID=75478295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557776A Active JP7855519B2 (ja) 2020-03-23 2021-03-22 がんを処置するための抗ｃｃｒ８抗体

Country Status (15)

Country Link
US (1) US20230119066A1 (enExample)
EP (1) EP4126950A1 (enExample)
JP (1) JP7855519B2 (enExample)
KR (1) KR20220157446A (enExample)
CN (1) CN115768792A (enExample)
AU (1) AU2021244200A1 (enExample)
BR (1) BR112022018636A2 (enExample)
CA (1) CA3172697A1 (enExample)
CL (2) CL2022002555A1 (enExample)
CO (1) CO2022013599A2 (enExample)
IL (1) IL296673A (enExample)
MX (1) MX2022011701A (enExample)
PE (1) PE20230821A1 (enExample)
TW (1) TW202202521A (enExample)
WO (1) WO2021194942A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
CA3198647A1 (en) 2020-10-16 2022-04-21 LaNova Medicines Limited Anti-ccr8 monoclonal antibodies and uses thereof
JPWO2022211046A1 (enExample) 2021-03-31 2022-10-06
IL308808A (en) 2021-06-04 2024-01-01 Amgen Inc Antibodies against CCR8 and their uses
EP4359442A4 (en) * 2021-06-25 2025-10-15 Nanjing Immunophage Biotech Co Ltd ANTI-CCR8 ANTIBODIES AND THEIR USES
FI4214240T3 (fi) 2021-07-27 2024-11-14 Abbvie Inc Ccr8-vasta-aineita
JP2024541680A (ja) * 2021-12-02 2024-11-08 ザイ ラボ （シャンハイ） カンパニー、リミテッド． Ｃｃｒ８抗原結合ユニット及びその使用
CN119930823A (zh) * 2021-12-23 2025-05-06 乐普创一生物科技（上海）有限公司 抗ccr8抗体及其应用
US20230279130A1 (en) * 2022-01-14 2023-09-07 Qilu Puget Sound Biotherapeutics Corporation Anti-ccr8 antibodies
TW202400648A (zh) * 2022-04-29 2024-01-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｃｒ８抗體及其用途
US20260028409A1 (en) 2022-05-24 2026-01-29 Bristol-Myers Squibb Company Antibodies that bind to human ccr8
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
CN115058387B (zh) * 2022-06-11 2023-12-01 重庆医科大学 一种人胚胎干细胞与前列腺癌细胞共培养制备抗前列腺癌药物的方法
WO2024026400A2 (en) * 2022-07-27 2024-02-01 Varian Medical Systems, Inc. Therapeutic combinations of titr effectors with radiation therapy
AU2023319869A1 (en) * 2022-08-04 2025-02-20 Beone Medicines I Gmbh Anti-ccr8 antibodies and methods of use
EP4573126A2 (en) * 2022-08-19 2025-06-25 Fibrogen, Inc. Anti-ccr8 antibodies and uses thereof
JP2025530159A (ja) 2022-09-09 2025-09-11 バイエル・アクチエンゲゼルシヤフト Ｃｃｒ８抗体の医学的使用および投与スケジュール
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062019A1 (en) 2022-09-21 2024-03-28 Synabs Anti-ccr8 antibodies and uses thereof
EP4590705A1 (en) 2022-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
AU2023356218A1 (en) * 2022-10-07 2025-04-24 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
KR20250091252A (ko) * 2022-10-28 2025-06-20 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-ccr8 항체 및 이의 용도
KR20250130296A (ko) 2022-11-22 2025-09-01 상하이 홍쳉 바이오파머수티컬 코., 엘티디. 항-ccr8 항체 및 이의 용도
CN118324910A (zh) * 2023-01-10 2024-07-12 北京天诺健成医药科技有限公司 Ccr8抗体的应用
AR131785A1 (es) 2023-02-06 2025-04-30 Bayer Ag Combinaciones de inhibidores de dgk (diacilglicerol quinasa)
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ｃｃｒ８を抗原として認識する二重特異性抗体
AU2024305430A1 (en) * 2023-06-12 2026-01-22 Nanjing Probio Biotech Co., Ltd. Antibody binding to human ccr8 and the use thereof
EP4590714A1 (en) 2023-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025061994A1 (en) 2023-09-21 2025-03-27 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
AU2024354737A1 (en) 2023-10-06 2026-04-16 Amgen Inc. Combination therapy for cancer treatment
WO2025082429A1 (zh) * 2023-10-17 2025-04-24 普米斯生物技术(珠海)有限公司 针对ccr8和ctla4的双特异性抗体
CN117186202B (zh) * 2023-11-08 2024-02-02 北京大学第三医院（北京大学第三临床医学院） 一种新细胞因子csbf及其在干眼治疗中的应用
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
CN119798438B (zh) * 2023-12-29 2025-11-18 广东东阳光药业股份有限公司 一种抗ccr8单克隆抗体及其应用
WO2025146065A1 (en) * 2024-01-05 2025-07-10 LaNova Medicines Limited Clinical regimens of anti-ccr8 antibodies
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025191147A1 (en) 2024-03-14 2025-09-18 Synabs Anti-ccr8 antibodies and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20260056209A1 (en) 2024-06-14 2026-02-26 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
JP2015535820A (ja) 2012-09-19 2015-12-17 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｋｉｒ３ｄｌ２結合剤
JP2017518260A (ja) 2014-04-18 2017-07-06 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク ヒト化抗−ｔｆ−抗原抗体
WO2018181425A1 (ja) 2017-03-29 2018-10-04 塩野義製薬株式会社 癌治療用医薬組成物
JP2019509054A (ja) 2016-01-08 2019-04-04 メディトープ バイオサイセンシーズ インク．Ｍｅｄｉｔｏｐｅ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己架橋性抗体
WO2020138489A1 (ja) 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
AU2014201371A1 (en) * 2007-10-31 2014-04-03 Xencor, Inc. Fc variants with altered binding to FcRn
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
NO2504364T3 (enExample) 2009-11-24 2018-01-06
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. NOVEL ANTI-PD-L1 ANTIBODIES
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
MX2018007295A (es) 2016-01-11 2019-03-28 Armo Biosciences Inc Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2018112033A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
WO2019157098A1 (en) 2018-02-06 2019-08-15 Advaxis, Inc. Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
CN110835374A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8×ctla-4双特异性抗体及其应用
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
JP2015535820A (ja) 2012-09-19 2015-12-17 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｋｉｒ３ｄｌ２結合剤
JP2017518260A (ja) 2014-04-18 2017-07-06 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク ヒト化抗−ｔｆ−抗原抗体
JP2019509054A (ja) 2016-01-08 2019-04-04 メディトープ バイオサイセンシーズ インク．Ｍｅｄｉｔｏｐｅ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己架橋性抗体
WO2018181425A1 (ja) 2017-03-29 2018-10-04 塩野義製薬株式会社 癌治療用医薬組成物
WO2020138489A1 (ja) 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体

Also Published As

Publication number Publication date
IL296673A (en) 2022-11-01
WO2021194942A9 (en) 2026-04-02
KR20220157446A (ko) 2022-11-29
US20230119066A1 (en) 2023-04-20
BR112022018636A2 (pt) 2023-01-31
CA3172697A1 (en) 2021-09-30
EP4126950A1 (en) 2023-02-08
CL2022002555A1 (es) 2023-03-17
JP2023519254A (ja) 2023-05-10
WO2021194942A1 (en) 2021-09-30
AU2021244200A1 (en) 2022-11-24
PE20230821A1 (es) 2023-05-19
CN115768792A (zh) 2023-03-07
MX2022011701A (es) 2022-10-07
CO2022013599A2 (es) 2022-10-11
TW202202521A (zh) 2022-01-16
CL2025003540A1 (es) 2025-12-12

Similar Documents

Publication Publication Date Title
JP2023519254A (ja) がんを処置するための抗ｃｃｒ８抗体
US12209128B2 (en) Anti-PD-L1 antibodies
US20230192847A1 (en) Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivo
US11660340B2 (en) Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11965026B2 (en) Anti-PD-L1 and IL-2 cytokines
JP7046973B2 (ja) 抗ｏｘ４０抗体およびその使用
EP3581651A1 (en) Anti-gprc5d antibody and molecule containing same
EP4214240B1 (en) Anti-ccr8 antibodies
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
JP2023513059A (ja) 抗ミューラー管ホルモン受容体２抗体及び使用方法
JP7692185B2 (ja) 抗ｃｄ４０抗体及びその用途
US20250122283A1 (en) Composition for cytotoxic t cell depletion
HK40026035A (en) Composition for cytotoxic t cell depletion
HK40014714A (en) Anti-gprc5d antibody and molecule containing same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240319

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240617

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260422

R150 Certificate of patent or registration of utility model

Ref document number: 7855519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150